Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Aggregation of alpha-synuclein (α-Syn) drives Parkinson's disease (PD), although the initial
stages of self-assembly and structural conversion have not been directly observed inside …

Abstract α-Synuclein (α-Syn) has been extensively studied for its structural and biophysical
properties owing to its pathophysiological role in Parkinson's disease (PD). Lewy bodies …

Protein aggregation causes α-synuclein to switch from its physiological role to a pathological
toxic gain of function. Under physiological conditions, monomeric α-synuclein improves ATP …

Parkinson's disease (PD), as the second most common neurodegenerative disease, is
caused by complex pathological processes and currently remains very difficult to treat. PD …

Oligomers which form during amyloid fibril assembly are considered to be key contributors
towards amyloid disease. However, understanding how such intermediates form, their …

Protein aggregation is a complex process resulting in the formation of heterogeneous
mixtures of aggregate populations that are closely linked to neurodegenerative conditions …

Protein misfolding and aggregation are characteristic of a wide range of neurodegenerative
disorders, including Alzheimer and Parkinson diseases. A hallmark of these diseases is the …

Despite the wealth of genomic and transcriptomic data in Parkinson's disease (PD), the
initial molecular events are unknown. Using LD score regression analysis, we show …